World's First Successful Human Eye Transplant and Novo Nordisk's Wegovy Shows Cardiovascular Benefits

Nov 13, 2023 19:58 CST Updated 19:58

LEADBIO

Medical Device Developer

1. LEADBIO Completes Nearly 100 Million Yuan in Series A Financing, Led by Panthera Capital

News on November 13: LEADBIO, a research and development platform for regenerative repair materials and artificial organs (hereinafter referred to as "LEADBIO"), has completed nearly 100 million yuan in Series A financing. This round of financing was led by Panthera Capital, with investments from Tylon Investment and BGI Win-Win, while existing shareholders Taiyu Investment and Boxin Capital also continued to increase their investments in this round. The funds from this Series A financing will mainly be used for the company’s registration clinical trials of its biological artificial blood vessels, while continuously advancing the R&D of other pipelines and further improving the construction of the company's technology achievement transformation platform.

2. Novo Nordisk's weight-loss drug Wegovy can reduce the risk of cardiovascular disease, and its usage scope may further expand.

Results from a study published on November 11 by Novo Nordisk show that its weight-loss drug Wegovy can reduce the incidence of cardiovascular disease. This indicates that, in addition to its known weight-loss effects, the drug offers additional benefits that could further expand its use. The full results of the study, named "Select," were published in The New England Journal of Medicine. The study involved more than 17,600 patients with a history of heart disease but without diabetes. Findings revealed that compared to a placebo, Wegovy reduced the occurrence rate of heart attacks, strokes, or cardiovascular death by 20%. Specifically, Wegovy decreased the risk of non-fatal heart attacks by 28%, non-fatal strokes by 7%, and cardiovascular-related deaths by 15%.

3. Breaking Through the Blood-Brain Barrier! Scholars from Peking Union Medical College, Chinese Academy of Medical Sciences Publish: New Drug for Glioma Treatment Discovered

Recently, researchers from Peking Union Medical College, Chinese Academy of Medical Sciences, published a research paper in the prestigious journal *Signal Transduction and Targeted Therapy*. The study not only identified Garcinol as an effective and safe drug for treating glioma but also revealed its underlying mechanism from the perspective of cytoskeletal homeostasis.

4. "SPEAR BIO" Secures Tens of Millions of Dollars in Seed Round Financing

Spear Bio Inc, a Massachusetts-based biotech company focusing on the research and development of next-generation proteomics and immunodiagnostics technologies, has recently completed a multi-million-dollar seed funding round. The round was successively led by Sequoia China Seed Fund and CDH VGC, with continued investment from existing shareholders such as Maverick Ventures and Yonhua Investment.

5. The First Successful Human Eye Transplant

Surgeons Perform World's First Eye Transplant. It’s not yet clear whether the recipient will be able to see with their new eye, but the operation is still an important step towards one day restoring vision to people who have suffered severe eye injuries.On May 27 this year, Eduardo Rodriguez from the NYU Langone Medical Center in New York, along with a team of over 140 people, performed an eye transplant surgery while conducting a partial face transplant on Aaron James, a 46-year-old power line worker from Arkansas. To date, there have been fewer than 50 face transplant surgeries worldwide, none of which involved the transplantation of eyes. Due to the complexity of the organ, full-eye transplantation was previously considered nearly impossible.

This article is only for academic sharing. Please indicate the source for reprinting. If there is any infringement, please contact WeChat: bioonSir for deletion or modification!